{
    "organizations": [],
    "uuid": "2af52cd649196494734d62131df21f58e864eea5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-karo-pharma-acquires-major-product/brief-karo-pharma-acquires-major-product-portfolio-for-eur-260-mln-idUSASM000JWP",
    "ord_in_thread": 0,
    "title": "Karo Pharma Acquires Major Product Portfolio for EUR 260 Mln",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Karo Pharma Ab:\n* KARO PHARMA ACQUIRES A MAJOR PRODUCT PORTFOLIO * ‍ACQUIRES A PRODUCT PORTFOLIO FROM DANISH PHARMACEUTICAL COMPANY LEO PHARMA A/S FOR 260 MEURO​\n* ‍ACQUISITION IS EFFECTIVE FROM 4TH OF APRIL 2018​ * SAYS ‍ACQUIRES A PRODUCT PORTFOLIO FROM DANISH PHARMACEUTICAL COMPANY LEO PHARMA A/S FOR 260 MEURO, EFFECTIVE FROM 4TH OF APRIL 2018.​\n* ‍ACQUISITION WILL BE FINANCED BY A COMBINATION OF NEW LOANS AND VIA A RIGHTS ISSUE​ Source text for Eikon: (Gdynia Newsroom)\n ",
    "published": "2018-03-01T15:06:00.000+02:00",
    "crawled": "2018-03-02T20:06:45.013+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "karo",
        "pharma",
        "ab",
        "karo",
        "pharma",
        "acquires",
        "major",
        "product",
        "portfolio",
        "product",
        "portfolio",
        "danish",
        "pharmaceutical",
        "company",
        "leo",
        "pharma",
        "effective",
        "4th",
        "april",
        "say",
        "product",
        "portfolio",
        "danish",
        "pharmaceutical",
        "company",
        "leo",
        "pharma",
        "meuro",
        "effective",
        "4th",
        "april",
        "financed",
        "combination",
        "new",
        "loan",
        "via",
        "right",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}